Table 2.
Relative Hazards and 95% Confidence Intervals (CI) for Times to Clinical AIDS, AIDS or Low CD4 T Count, and Death among MACS HIV-1 Seroconverters
| |
AIDS |
AIDS or CD4 <200 |
Death |
|||
|---|---|---|---|---|---|---|
| RH | 95% CI | RH | 95% CI | RH | 95% CI | |
| Model 1 (n = 361) | ||||||
| Presence of anti-R7V antibody | 1.44 | (1.08, 1.94) | 1.72 | (1.31, 2.25) | 1.54 | (1.14, 2.08) |
| HAART use | 0.31 | (0.19, 0.51) | 0.14 | (0.07, 0.26) | 0.34 | (0.22, 0.52) |
| CD4 T cell count (per change of 50 cells/μl)a | 0.96 | (0.93, 0.99) | 0.96 | (0.93, 0.99) | 0.97 | (0.95, 1.00) |
| Model 2 (n = 333)b | ||||||
| Presence of anti-R7V antibody | 1.07 | (0.78, 1.46) | 1.31 | (0.98, 1.75) | 1.23 | (0.89, 1.70) |
| HAART use | 0.28 | (0.17, 0.47) | 0.12 | (0.06, 0.24) | 0.29 | (0.18, 0.45) |
| CCR5 32 | 0.85 | (0.55, 1.31) | 0.86 | (0.58, 1.25) | 0.60 | (0.37, 0.98) |
| CD4 T cell count (per change of 50 cells/μl)a | 0.97 | (0.94, 1.00) | 0.97 | (0.94, 0.99) | 0.99 | (0.96, 1.02) |
| Log10 HIV-1 RNA (per increase of one log)a | 2.08 | (1.63, 2.64) | 1.79 | (1.44, 2.22) | 1.77 | (1.39, 2.24) |
a
Values at visit at which anti-R7VAb was measured.
b
Model 2 excludes participants with no CCR5 32 information or with no HIV-1 RNA information at study visit.